AU Patent

AU2020220135C1 — Use of cannabinoids in the treatment of epilepsy

Assigned to Jazz Pharmaceuticals Research UK Ltd · Expires 2024-12-05 · 1y expired

What this patent protects

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of "treatment-resistant epilepsy" (TRE). In 5 particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dra…

USPTO Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of "treatment-resistant epilepsy" (TRE). In 5 particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). 0

Drugs covered by this patent

Patent Metadata

Patent number
AU2020220135C1
Jurisdiction
AU
Classification
—
Expires
2024-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Research UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.